Meibomian Gland Dysfunction Market
According to Intent Market Research, the Meibomian Gland Dysfunction Market is expected to grow from USD 5.5 billion in 2024-e at a CAGR of 5.3% to touch USD 7.8 billion by 2030. The Meibomian Gland Dysfunction Market is dominated by key players such as Allergan, Inc. (AbbVie), Novartis AG, Johnson & Johnson Vision, Ocular Therapeutix, Inc., Avedro, Inc. (Glaukos Corporation) and TearLab Corporation.